Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 64Neoplasms 38Venous Thromboembolism 29Leukemia 21Anemia, Refractory, with Excess of Blasts 20Myelodysplastic Syndromes 19Lymphoma 14Thrombocytopenia 13Multiple Myeloma 12Leukemia, Myelomonocytic, Chronic 12Venous Thrombosis 11Pulmonary Embolism 11Febrile Neutropenia 11Breast Neoplasms 10Myeloproliferative Disorders 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Neoplasms, Plasma Cell 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Primary Myelofibrosis 6Neutropenia 6Hodgkin Disease 6Hemophilia A 6Lung Neoplasms 5Anemia, Refractory 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Precancerous Conditions 4Lymphoproliferative Disorders 4

Interventions

apixaban 1Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Mesenteric Ischemia × Classical hematology × Clear all
NCT02585713 2020-08-04

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

Academic and Community Cancer Research United

Phase 3 Completed
300 enrolled 11 charts
Classical hematology

Neoplasm Metastasis, Neoplasms, Pulmonary Embolism, Venous Thrombosis, Intracranial Thrombosis, Venous Thromboembolism, Mesenteric Ischemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡